Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14810MR)

This product GTTS-WQ14810MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13430MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ15256MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ6035MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ2227MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ4646MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ4363MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ2982MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ13684MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW